ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1609

Telomere Length and Coronary Artery Atherosclerosis in Patients with Systemic Lupus Erythematosus

Nathan Stein1, Joseph F. Solus1, Annette M. Oeser1, Paolo Raggi2, C Michael Stein1 and Michelle J. Ormseth3, 1Vanderbilt University Medical Center, Nashville, TN, 2University of Alberta, Edmonton, AB, Canada, 3Medicine, Vanderbilt University Medical Center, Nashville, TN

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: Atherosclerosis, Cardiovascular disease, metabolic syndrome and systemic lupus erythematosus (SLE), Telomeres

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 6, 2017

Title: Systemic Lupus Erythematosus – Clinical Aspects and Treatment Poster II: Damage and Comorbidities

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose:  Coronary atherosclerosis increases with age but is more prevalent in patients with systemic lupus erythematosus (SLE) independent of chronological age; this increased prevalence has been suggested to reflect accelerated biological aging in SLE. Telomeres protect chromosomal ends from shortening after replication, and telomere length is indicative of biological age. We examined the hypothesis that reduced telomere length, reflecting accelerated biological aging, is associated with inflammation, disease activity and damage, cardiometabolic risk factors, and coronary atherosclerosis in patients with SLE.

Methods: We performed a cross-sectional study in 126 patients with SLE. Telomere length was measured from whole blood DNA using real-time quantitative PCR as telomeric product to a single-copy gene product ratio (T/S ratio). Inflammation was assessed by high sensitivity C-reactive protein (CRP). SLE disease activity and damage were assessed by Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) and the Systemic Lupus International Collaborating Clinics Classification Criteria (SLICC), respectively. Homeostatic Model Assessment (HOMA) was used to assess degree of insulin resistance. Framingham Risk Score (FRS) was determined based on the American Heart Association criteria. Coronary artery calcium score was measured by electron beam computed tomography. Spearman correlation and linear or logistic regression models adjusting for age, race, and sex were used to determine the association between telomere length and clinical variables.  

Results:  Patients with SLE were predominantly female (91%) and Caucasian (65%) with median age 41 years. Telomere length was inversely associated with age (ρ =-0.43, P<0.001) and CRP (ρ=-0.31, P<0.001, Padj<0.001) but not with SLEDAI or SLICC scores (Table). Higher triglycerides (ρ=-0.21, P=0.02 Padj=0.007) and FRS (ρ=-0.43, P<0.001, Padj=0.03) were inversely associated with telomere length independent of age, race and sex. Systolic blood pressure and waist-hip ratio were inversely associated with telomere length, but the relationship was attenuated after adjustment. High-density and low density lipoproteins, diastolic blood pressure, HOMA, and coronary artery calcium score were not associated with telomere length (Table).

Conclusion: Telomere length was significantly inversely associated with chronological age in SLE; it was also inversely associated with some cardiometabolic risk factors such as triglycerides, FRS, and CRP independent of age, race, and sex.  However, coronary artery calcium score was not independently associated with telomere length, suggesting that factors other than accelerated biological aging are responsible for increased atherosclerosis in SLE.

 

Table. Relationship between telomere length and disease-related and cardiometabolic risk factors in SLE

 

Rho (ρ)

P

Adjusted P*

Age

-0.43

<0.001

–

SLEDAI

0.13

0.14

0.59

SLICC

-0.07

0.47

0.37

CRP

-0.31

<0.001

<0.001

Systolic BP

-0.25

0.005

0.13

Diastolic BP

-0.10

0.28

0.40

Waist-hip ratio

-0.25

0.006

0.06

HOMA

-0.10

0.28

0.20

Triglycerides

-0.21

0.02

0.007

HDL

0.04

0.68

0.11

LDL

0.02

0.86

0.88

FRS

-0.43

<0.001

0.03

Coronary calcium

-0.13

0.15

0.91

*Adjusted for age, race and sex. SLEDAI= Systemic Lupus Erythematosus Disease Activity Index, SLICC= Systemic Lupus International Collaborating Clinics Classification Criteria, CRP=high sensitivity C-reactive protein, BP=blood pressure, HOMA= Homeostatic Model Assessment, HDL=high density lipoprotein, LDL= low density lipoprotein, FRS= Framingham risk score.

 


Disclosure: N. Stein, None; J. F. Solus, None; A. M. Oeser, None; P. Raggi, None; C. M. Stein, None; M. J. Ormseth, None.

To cite this abstract in AMA style:

Stein N, Solus JF, Oeser AM, Raggi P, Stein CM, Ormseth MJ. Telomere Length and Coronary Artery Atherosclerosis in Patients with Systemic Lupus Erythematosus [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/telomere-length-and-coronary-artery-atherosclerosis-in-patients-with-systemic-lupus-erythematosus/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/telomere-length-and-coronary-artery-atherosclerosis-in-patients-with-systemic-lupus-erythematosus/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology